Single-dose pharmacokinetics of ceftriaxone were determined in 19 patients with proven bacterial meningitis. The dosage was 50 mg of ceftriaxone per kg. The plasma concentration time curve declined in a biexponential manner. The mean peak plasma concentration was 207 ,tg/ml, and the elimination half-life was 4 h. In 12 patients, multiple-dose pharmacokinetics were determined after a loading dose of 75 mg of ceftriaxone per kg, followed by 50-mg/kg doses every 8 h in 5 patients or every 12 h in 7 patients. The mean peak plasma concentration was 230 Fg/ml after the first dose and 263 ,ug/ml after the last dose. Of 12 patients, 5 had trough values that were larger after multiple doses than after a single dose. Mean penetration of ceftriaxone into cerebrospinal fluid was 3.1%. The median cerebrospinal fluid bactericidal titer against the patients pathogens was >1:1,024 and <1:2,048. The drug was well tolerated without adverse effects.
mase-producing strains of H. influenzae (1, 6, 14) and the appearance of S. pneumoniae strains which are resistant to penicillin (2) (3) (4) (5) 8) , the initial treatment of bacterial meningitis currently consists of ampicillin and chloramphenicol.
However, strains of H. influenzae resistant to both ampicillin and chloramphenicol have been recently reported (12, 24) . These changes in susceptibilities of the principal meningitis pathogens have prompted the search for alternative antibiotics.
Ceftriaxone (Ro 13-9904) is a cephalosporin derivative with broad antimicrobial activity, including the organisms that cause bacterial meningitis (10, 20) . In experimentally induced meningitis in rabbits, ceftriaxone exhibited greater bactericidal activity and a larger reduction in the concentrations of H. influenzae and S. pneumoniae in the cerebrospinal fluid (CSF) than did moxalactam, cefoperazone, cefuroxime, or chloramphenicol (15) .
For these reasons, we studied the pharmacokinetics and bactericidal activity of ceftriaxone in infants and children with bacterial meningitis. mg/kg was given as a 10-to 15-min intravenous infusion of a solution containing 40 to 50 mg of ceftriaxone per ml. One patient received a dose of 75 mg/kg. Ceftriaxone was given on day 1 through day 3 of meningitis therapy in addition to conventional treatment with ampicillin, chloramphenicol, or both.
Multiple doses of ceftriaxone were administered to 12 patients with a loading dose of 75 mg/kg followed by 50 mg/kg doses given either every 8 h (5 patients) or every 12 h (7 patients). Ceftriaxone was given for 4 to 5 days, whereas ampicillin was administered for the entire 10-day period. Samples from the patient receiving chloramphenicol were analyzed for ceftriaxone by using a Morganella morganii strain resistant to chloramphenicol.
Plasma samples were obtained before, at completion of the 10-to 15-min infusion and at 0.5, 1, 2, 4, and 6 h after the infusion. In those patients who received multiple doses, a sample was collected at 8 or at 12 h after the dose on first and last day of the study. In some patients, samples were obtained 24 and 48 h after therapy was stopped. Plasma samples were collected either by a heparin lock or by finger stick.
A CSF sample was obtained by a randomization schedule at 0.5, 2, 4, or 6 h postinfusion of single doses and at 8 or 12 h in those patients who received multiple doses. In the latter patients, a CSF sample was also obtained on the last day of ceftriaxone therapy; the interval after the dose was the same for both samples in each patient. Ceftriaxone assay. Samples were stored at -20°C until assayed within 4 days of collection. Plasma and CSF were assayed by the agar diffusion micromethod (22) , using Escherichia coli Ro 1346 (provided by Hoffmann-LaRoche, Inc.) or M. morganii as the test strain.
Because ceftriaxone is 95% protein bound (20) , plasma samples and laboratory standards were prepared in 100o pooled human plasma. CSF samples were diluted in 1% phosphate buffer, pH 6.0, and compared with standards prepared in buffer. Ampicillin was inactivated by addition of penicillinase (Penase, Difco Laboratories) to the samples. Phannacokinetic analysis. Plasma curves were analyzed by the NONLIN least-squares computer program (21; C. M. Metzler, G. L. Elfring, and A. J. McEwen, Biometrics 30:562, 1974). The plasma concentration time curves were biexponential and were best fitted to a two-compartment pharmacokinetic model (7, 13, 17) .
RESULTS
Susceptibilities of the bacterial isolates from CSF cultures of the 32 patients to ceftriaxone are shown in Table 1 .
The median minimal bactericidal concentration of ceftriaxone (0.002 ,ug/ml) was one-sixtieth of that of ampicillin (0.125 ,ug/ml) for (-lactamase-negative H. influenzae strains. A ceftriaxone concentration of s0.002 ,ug/ml killed the three (-lactamase-positive H. influenzae strains compared with an ampicillin concentration of 5 to -8 ,ug/ml. Against the few N. meningitidis and S. pneumoniae strains tested, ceftriaxone was 5-to 20-fold more active than ampicillin.
Single-dose pharmacokinetics. Plasma concentrations of ceftriaxone at completion of the 10-to 15-min infusion were from 120 to 375 p.g/ml 12 Lg/ml and a infants and children with meningitis. Plasma concentration time curves were constructed curve was from assayed samples obtained after the first vo-compart-and last doses ( Fig. 2 and 3) . In all patients, the 17) (correla-initial 75-mg/lkg dose was followed by 50-mg/kg s an initial doses given intravenously every 8 or 12 h. Peak nting the a-(end of infusion) concentrations in plasma were of 0.25 h, from 145 to 400 ,ug/ml (mean, 230 ± 70.2 pg/ml) ation phase after the first dose and from 150 to 410 pg/ml la clearance (mean, 263 ± 79.8 pg/ml) after the last dose. In 8 d the appar-of 10 patients, peak concentrations were larger i ml/kg. Be-after multiple doses than after the first dose. lected over After the first dose, the ceftriaxone concentra-:se pharma-tions at 12 h were from 23 to 46 pg/ml (mean, -curate.
33.9 ± 8.5 p.g/ml), whereas the predose (approxi 19 infants imately 12 h after the previous dose) values after Irhe half-life multiple doses administered every 12 h were i calculated from 13 to 52.5 ,ug/ml (mean, 32.3 ± 18.7 ,ug/ml). as observed Two of five patients had slightly larger plasma .an penetra-concentrations after multiple than after single 3.1%, ex-doses of the drug. When ceftriaxone was given IS under the every 8 h, trough concentrations were from 45 to 00. A CSF 75 pg/nml (mean, 54.4 ± 12.6 pg//ml) after the first Lsured at 40 dose and from 46 to 85 ug/nml (mean, 70.5 + 14.7 a 75-mg/kg pg/ml) after multiple doses. The plasma concentrations 24 h after therapy was stopped ranged from <0.075 to 17.0 ,ug/ml (mean, 6.6 ± 6.5 ,ug/ml). At 48 h after the last dose of ceftriaxone, plasma levels ranged from <0.075 to 1.5 ,ug/ml (mean, 0.96 ± 0.71 ,ug/ml).
These plasma concentration time curves were not subjected to pharmacokinetic analysis because of the relatively few subjects studied, The mean concentrations in CSF when ceftriaxone was administered every 8 h ranged from 1.8 ,ug/ml at 0.5 h to 7.2 ,ug/ml at 6 h after the first dose and from 5.2 ,ug/ml at 0.5 h to 4.8 ,g/ ml at 6 h after multiple doses (Table 2 ). When ceftriaxone was given every 12 h, the mean CSF concentration in four patients 12 h after the first dose was 2.8 ± 1.1 ,ug/ml and 1.6 ± 0.73 ,ug/ml after multiple doses ( Table 2) .
The bactericidal titers in CSF after first and multiple doses were ,1:512 against the pathogens causing meningitis. In 10 specimens, including 3 of 4 specimens obtained 12 h after the dose, the bactericidal titers were -1:1,024 (Table 3).
Safety and tolerance. The administration of ceftriaxone was well tolerated by all of the patients, and there were no adverse reactions. distribution of ceftriaxone increased nonlinearly with dose, whereas serum half-life was independent of dose. The pharmacokinetics of this thirdgeneration cephalosporin in adults (23) were strikingly different from those computed in infants and children in our study (Table 4 ) and in the study of Schaad and Stoeckel (19) . Our data indicate that the penetration of ceftriaxone into the CSF is similar to that of penicillin G in infants and children with meningitis (9) and is considerably smaller than that of other Plactams such as ampicillin (25) or moxalactam (11, 18) . These data in infants are similar to the penetration values for ceftriaxone observed in experimental H. influenzae or S. pneumoniae meningitis in rabbits (15) . In that animal model, penetration of ceftriaxone into CSF was smaller than that of the other new P-lactam antibiotics.
DISCUSSION
However, CSF bactericidal activity against H. influenzae and S. pneumoniae was substantially greater with ceftriaxone (15) . The median bactericidal titer in our study patients was .1:1,024 and '1:2,048, which exceeds by manyfold the bactericidal titer of ampicillin against P-lactamase negative H. influenzae.
Ceftriaxone has been previously used for ther- On the basis of the information from experimental meningitis and of our pharmacokinetic data in pediatric patients with meningitis, we have initiated a study of the efficacy and safety of ceftriaxone in infants and children with meningitis. The regimen selected is of an initial 75-mg/kg dose, followed by 50-mg/kg doses given intravenously every 12 h. We have shown that this schedule produces peak and trough CSF bactericidal titers of -1:512 against the three principal pathogens causing meningitis.
